Israeli Ministry Approves Phase 2/3 Trial of Silexion's SIL204 for Locally Advanced Pancreatic Cancer
ByAinvest
Tuesday, Mar 24, 2026 9:49 am ET1min read
SLXN--
Silexion Therapeutics has received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for its SIL204 treatment in locally advanced pancreatic cancer. This marks a significant regulatory milestone and advances the company into clinical-stage development. SIL204 targets KRAS mutations present in over 90% of pancreatic cancers and has shown strong positive preclinical results and successful completion of toxicology studies. The company expects to initiate human clinical trials in the second quarter of 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet